Gyre Therapeutics, Inc. (GYRE)
The price, the headline numbers and the latest news, in one place.
Gyre Therapeutics, Inc. (GYRE) Stock Price, Analysis & Data
| Bid | 4.59 |
| Market Cap | 674M |
| Revenue (ttm) | 110M |
| Net Income (ttm) | -19.9M |
| 4.82 | |
| -0.21 | |
| n/a | |
| 106 | |
| P/B (ttm) | 6.25 |
| P/S (ttm) | 6.14 |
| Earnings Date | Mar 17, 2025 |
| Ask | 8.17 |
| Volume | 54,546 |
| Avg. Volume (20D) | 78,965 |
| Open | 6.51 |
| Previous Close | 6.57 |
| Day's Range | 6.32 - 6.57 |
| 52-Week Range | 5.44 - 9.42 |
| Analyst | n/a |
| Price Target | 18 (178.21%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GYRE
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural d...
Financial Performance
In 2025, Gyre Therapeutics's revenue was 116.59M, an increase of 10.24% compared to the previous year's 105.76M. Earnings were 5.03M, a decrease of -58.4%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for GYRE stock is "null". The 12-month stock price forecast is 18, which is upside of 178.21% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $29.11M misses estimates by $0, with -2.12% YoY decline.
- EPS of -0.12 misses estimates by -0.06, with -Infinity% YoY decline.
Analysts project revenue of ... Upgrade
